Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22195
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorKatopodis, K.en
dc.contributor.authorPappas, M.en
dc.contributor.authorSferopoulos, G.en
dc.contributor.authorTzallas, C.en
dc.contributor.authorTsolas, O.en
dc.contributor.authorSiamopoulos, K. C.en
dc.date.accessioned2015-11-24T19:22:51Z-
dc.date.available2015-11-24T19:22:51Z-
dc.identifier.issn0250-8095-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22195-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectApolipoproteins/blooden
dc.subjectBuffersen
dc.subjectCarnitine/*administration & dosage/blooden
dc.subjectCholesterol/blooden
dc.subjectFemaleen
dc.subjectHemodialysis Solutionsen
dc.subjectHumansen
dc.subjectHypertriglyceridemia/drug therapy/etiologyen
dc.subjectKidney Failure, Chronic/blood/complications/therapyen
dc.subjectLipids/*blooden
dc.subjectLipoproteins/blooden
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subject*Renal Dialysisen
dc.subjectTriglycerides/blooden
dc.titleEffect of L-carnitine supplementation on lipid parameters in hemodialysis patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9730566-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000013386-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1998-
heal.abstractIt has been reported that cumulative carnitine losses through dialysis membranes may worsen hyperlipidemia during long-term hemodialysis. However, carnitine supplementation has not shown a consistent beneficial response. We undertook the present study to determine if there is any hypolipidemic effect of L-carnitine on Greek dialysis patients in concert with the dialysate buffer composition (acetate or bicarbonate). A total of 28 patients (16 male, 12 female), mean age 43 years (range 21-61), with end-stage renal disease on maintenance hemodialysis for a mean period of 25 months (range 7-84) were studied. The dialysis schedule was 4 h, 3 times/week using cuprophane hollow-fiber dialyzers and acetate (n = 14) or bicarbonate (n = 14) dialysate. In all patients L-carnitine (5 mg/kg body weight) was infused intravenously 3 times/week at the end of each hemodialysis session. Blood samples for carnitine and lipid determinations were obtained before treatment, and 3 and 6 months following treatment. Even though L-carnitine did not modify most of the serum lipid levels, a significant decrease in serum triglycerides was evident in the whole group of patients (from 225 +/- 76 to 201 +/- 75 mg/dl, p = 0.03). Furthermore, L-carnitine could decrease serum triglycerides only in hypertriglyceridemic patients (from 260 +/- 64 to 226 +/- 82 mg/dl, p < 0.05). L-Carnitine resulted in a reduction of serum triglycerides in both patients on bicarbonate and on acetate dialysis, while there were no significant differences in the changes of lipid parameters after L-carnitine between the two groups of hemodialysis patients. We conclude that relatively low doses of L-carnitine supplementation could contribute to the management of some hypertriglyceridemic hemodialysis patients.en
heal.journalNameAm J Nephrolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons